Videos
click on the image above to watch the webcast
(to view the webcast in fullscreen, click on the bottom right square icon underneath the YouTube logo)
This video is the fifth in a five-part series that focuses on new strategies for multiple myeloma care. It was presented during the…
Videos
Double click on the image above to view the video:
Download the slides here:
Diagnosis and Risk Stratification of Plasma Cell Disorders: To Treat or Not to Treat
…
Videos
Is it possible for bone lesions to progress even when all other tests look good?
BOTTOM LINE:
In this week’s video, Dr. Durie discusses bone disease in myeloma patients and the importance of continued bone lesion monitoring.
Transcript:
This week’s “…
News Article
Los Angeles, CA, Dec. 4, 2019—The International Myeloma Foundation (IMF) announced today that four important research studies supported by the organization's Black Swan Research Initiative® (BSRI) to find a cure for multiple myeloma…
Event
Dr. Brian G.M. Durie discusses key takeaways from the annual conference and explains how this new and important information relates to myeloma patients, caregivers, and other members of the myeloma community.
Thursday January 9, 2020
4:00 pm Pacific/5:00 pm Mountain
6:00 pm Central/7:00 pm…
Event
Patients, caregivers, and doctors around the world can view the IMF's popular livestream IMWG Conference Series, "Making Sense of Treatment" from Orlando, FL. IMF Chairman Dr. Brian G.M. Durie, Dr. Maria V. Mateos, and IMF Chief Medical Officer Dr. Joseph Mikhael distill, debate, and discuss …
Event
Join us for this year’s International Myeloma Foundation and Clinical Care Options cosponsored symposium, where an esteemed panel of international experts will offer their perspectives on practice-changing data and optimal management of patients with myeloma.
Friday, December 6, 2019
1:00 PM ET…
Videos
In this week’s video, Dr. Durie explains what a "BEAT" is, and how it is similar to a BiTE.
BOTTOM LINE:
A BEAT is a bispecific antibody that binds T-cells to myeloma cells.
Transcript:
This week's "Ask Dr. Durie" comes from. A patient who wants to…
News Article
If you have been following what has been going on in Washington lately, you have likely heard a lot about government shutdowns and continuing resolutions (CRs). The federal government would have run out of funding on November 21st had Congress not acted. A short-term CR will temporarily fund the…
Videos
In this week’s video, Dr. Durie discusses the CANDOR trial, a randomized phase III clinical trial studying the three-drug combination therapy of Kyprolis®, Darzalex®, and dexamethasone.
BOTTOM LINE:
The CANDOR trial is a randomized phase III clinical trial showing…
Videos
In this week’s video, Dr. Durie discusses the importance of resilience when overcoming the challenges that come with a myeloma diagnosis, and the support available to you.
BOTTOM LINE:
Maintaining one’s resilience when facing the challenges of a myeloma diagnosis is…
News Article
On October 15, 2019, the International Myeloma Foundation’s Advocacy Team hosted the first-ever “All Cancers Congress” at the National Press Club in Washington, D.C..
The event gave the cancer advocacy community a chance to discuss their individual advocacy efforts and legislative…
Page
The International Myeloma Foundation brings myeloma support group leaders and patients to the annual meeting of the American Society of Hematology (ASH), an exciting convergence of over 30,000 health care professionals from around the world. Start following the IMF ASH team members now on social…
News Article
This year, the International Myeloma Foundation (IMF) has received the highest 4-star rating for the 15th time from Charity Navigator, the largest independent charity evaluator in the U.S.
Michael Thatcher, Charity Navigator President and CEO, stated, “Attaining a 4-star rating…
News Article
On September 26, 2019, the Food and Drug Administration approved daratumumab (DARZALEX, Janssen) for adult patients with multiple myeloma in combination with bortezomib, thalidomide, and dexamethasone in newly diagnosed patients who are eligible for autologous stem cell transplant (ASCT).
News Article
The 7TH ANNUAL MIRACLES FOR MYELOMA 5K RUN/WALK will take place on Saturday, September 21, 2019. Last year, at the 6th Annual Miracles for Myeloma Run/Walk, over $80,000 was raised in pursuit of the cure for Multiple Myeloma, and a Senior Brian D. Novis Research Grant was awarded by the…
Page
Name: Brian G.M, Durie, MDBirth: Scotland, 1942Death: Scotland, 2025POSITIONS AND TITLES HELDInternational Myeloma Foundation (IMF)Co-Founder and Board MemberCedars-Sinai Outpatient Cancer Center at the Samuel Oschin Comprehensive Cancer Institute…
Videos
In this week’s video, Dr. Brian G.M. Durie discusses just how close we are to discovering a method of preventing both MGUS, and the transition from MGUS to active myeloma.
BOTTOM LINE:
There is a high likelihood that in the coming years, both the development MGUS and the…
Page
To prevent multiple myeloma, scientists are investigating what causes the disease. Recent evidence has linked myeloma with exposure to toxic chemicals. Several viruses have been identified as potential triggers. We also now know there is a 2- to 4-…
Videos
.button {
background-color: #4CAF50;
border: none;
color: white;
padding: 15px 25px;
text-align: center;
font-size: 18px;
font-weight: bold;
cursor: pointer;
}
.button:hover {
background-color: green;
}
Double-click on the image above to view a replay of…
Videos
In this week’s video, Dr. Durie explains how a previously ineffective drug can work in a different combination therapy.
BOTTOM LINE:
Yes, a drug used in a previous combination that is no longer working can be used effectively as part of another combination therapy…
Videos
In this week’s video, IMF’s Chairman of the Board Brian G.M. Durie, MD, explains why patients should stick to their prescribed treatment regimens.
BOTTOM LINE:
The earlier you begin treatment with your best recommended therapy, the better the chances are for a more…
Videos
In this video, Dr. Brian G.M. Durie defines three types of potential cures for myeloma and describes how the IMF’s Black Swan Research Initiative® may achieve one of these types of cures in the future.
BOTTOM LINE:
There are three ways cure can be considered: functional…
Page
The International Myeloma Foundation (IMF) is firmly committed to compliance with the Americans with Disabilities Act. As part of this committment, the IMF has taken steps to make our website as accessible as possible for all users. We continue to work diligently with…
Page
(function(t,e,s,o){var n,c,l;t.SMCX=t.SMCX||[],e.getElementById(o)||(n=e.getElementsByTagName(s),c=n[n.length-1],l=e.createElement(s),l.type="text/javascript",l.async=!0,l.id=o,l.src=["https:"===location.protocol?"https://":"http://","widget.surveymonkey.com/collect/website/js/…
Videos
In this week’s video, Dr. Durie discusses the importance of consulting with a myeloma expert, current treatment trends, and being resilient.
BOTTOM LINE:
Be resilient. Educate yourself as much as possible about multiple myeloma, your diagnosis, testing, and the…
Videos
In this week's video, Dr. Durie discusses how to tell if you are refractory to the drug Revlimid® and what other combination therapies could be available as an alternative.
BOTTOM LINE:
Determine with your doctor if you are refractory to Revlimid®. If so, discuss…
Page
People with multiple myeloma are living longer with improved treatments. Thus, proper health maintenance practices are increasingly important. Provided are resources and information to assist multiple myeloma health care providers in navigating patients’ long-term health care.
Important…
Page
Myeloma patients should be considered for clinical trials during all phases of treatment. The novel agents available for myeloma have all been developed through the clinical trials process, substantially increasing survival of myeloma patients over a short period of time.…
Page
The myeloma patient will require support to alleviate the physical and emotional impact of living with this illness. The IMF encourages early use of supportive care measures, which are just as important as initiating therapy. This section covers care guidelines for managing symptoms and side…
Page
Shared Decision Making
Deciding that treatment is necessary is the most pressing initial decision post-diagnosis. Since all treatments have side effects, treatment must be medically necessary and the benefits of treatment must outweigh unwanted side effects. The provider and the patient should…
Page
In 2015, the revised international staging system (R-ISS) from the International Myeloma Working Group (IMWG) was published, which provides the most up-to-date tool for stratifying multiple myeloma patient risk based on prognosis. On October 2020, the…
Page
The progression of myeloma varies greatly from person to person. Accurate diagnosis and risk stratification are essential in…
Page
Empower Yourself
To make good decisions about your care with your healthcare team, learn as much as you can about myeloma and its treatments. You can do so by accessing IMF publications here or reaching out to an IMF InfoLine at 1-800-452-CURE (2873) or at …
Event
.button {
background-color: #207588;
border: none;
color: #FFFFFF;
text-align: center;
font-size: 16px;
font-weight: 600;
padding-top: 10px;
padding-right: 20px;
padding-bottom: 7.5px;
padding-left: 20px;
cursor: pointer;
border-radius: 50px;
text-decoration…
Page
The IMF Leads the ChargeThe International Myeloma Foundation is committed to the search for a cure or cures. It is central to our mission: Accelerating the prevention and cure of myeloma and improving the quality of life for patients and families.
News Article
On Wednesday, the U.S. Food and Drug Administration (FDA) granted accelerated approval to selinexor (XPOVIO™) in combination with dexamethasone for the treatment of relapsed/…
Videos
In this week's video, Dr. Durie discusses what effect a new treatment can have on your myeloma protein levels, and when it can be time to consider changing your treatment regimen with your doctor.
BOTTOM LINE:
Venetoclax will move forward as a “targeted” precision…
Videos
In this week's video, Dr. Durie discusses what effect a new treatment can have on your myeloma protein levels, and when it can be time to consider changing your treatment regimen with your doctor.
BOTTOM LINE:
Carefully discuss the results of your myeloma protein…
News Article
The FDA has approved the combination of daratumumab (Darzalex) with lenalidomide (Revlimid) and dexamethasone (DRd) for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation (ASCT).
Videos
In this week’s video, Dr. Brian G.M. Durie discusses how denosumab works against RANK ligand and what happens when the treatment is suddenly stopped.
BOTTOM LINE:
Take caution when stopping denosumab. Talk to your doctor about the use of a bridging treatment such as…